These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30994430)

  • 1. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria.
    Williams PCM; Waichungo J; Gordon NC; Sharland M; Murunga S; Kamau A; Berkley JA
    J Med Microbiol; 2019 May; 68(5):711-719. PubMed ID: 30994430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
    Tariq TM
    J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study.
    Bielen L; Likić R; Erdeljić V; Mareković I; Firis N; Grgić-Medić M; Godan A; Tomić I; Hunjak B; Markotić A; Bejuk D; Tičić V; Balzar S; Bedenić B
    Croat Med J; 2018 Apr; 59(2):56-64. PubMed ID: 29740989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of
    Suich J; Mawer D; van der Woude M; Wearmouth D; Burns P; Smeets T; Barlow G
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35476672
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates.
    Demir T; Buyukguclu T
    J Glob Antimicrob Resist; 2017 Mar; 8():164-168. PubMed ID: 28167307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
    Patwardhan V; Singh S
    Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of Fosfomycin Susceptibility in Extended Spectrum Beta-Lactamase Producing Enteric Bacteria by Disk Diffusion, Automated System and Agar Dilütion Kit].
    Soydan G; Görgülü Y; Öztürk C
    Mikrobiyol Bul; 2021 Oct; 55(4):617-625. PubMed ID: 34666660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.
    Perdigão-Neto LV; Oliveira MS; Rizek CF; Carrilho CM; Costa SF; Levin AS
    Antimicrob Agents Chemother; 2014; 58(3):1763-7. PubMed ID: 24323469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.
    Kakaraskoska Boceska B; Vilken T; Xavier BB; Kostyanev T; Lin Q; Lammens C; Ellis S; O'Brien S; da Costa RMA; Cook A; Russell N; Bielicki J; Riddell A; Stohr W; Walker AS; Berezin EN; Roilides E; De Luca M; Romani L; Ballot D; Dramowski A; Wadula J; Lochindarat S; Boonkasidecha S; Namiiro F; Ngoc HTB; Tran MD; Cressey TR; Preedisripipat K; Berkley JA; Musyimi R; Zarras C; Nana T; Whitelaw A; da Silva CB; Jaglal P; Ssengooba W; Saha SK; Islam MS; Mussi-Pinhata MM; Carvalheiro CG; Piddock LJV; Heath PT; Malhotra-Kumar S; Sharland M; Glupczynski Y; Goossens H
    Nat Commun; 2024 May; 15(1):3947. PubMed ID: 38729951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong.
    Ip M; Lai CK; Fung KSC; Wong KT; Zhu C; Van de Velde S; Tsang DN; Hawkey P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2491-2494. PubMed ID: 28840351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).
    Cantón R; Loza E; Aznar J; Calvo J; Cercenado E; Cisterna R; Romo FG; Hontangas JL; Calvo CR; Barrenechea AI; Tubau F; Weber I; Yuste P; Cavanillas R;
    Rev Esp Quimioter; 2011 Dec; 24(4):223-32. PubMed ID: 22173194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.